company background image
IDOGEN logo

Idogen OM:IDOGEN Stock Report

Last Price

SEK 0.12

Market Cap

SEK 12.6m

7D

-5.5%

1Y

-62.9%

Updated

11 Jul, 2023

Data

Company Financials +

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

IDOGEN Stock Overview

Idogen AB (publ), a biotechnology company, develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs, and the body’s own cells or tissues in Sweden. More details

IDOGEN fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Idogen AB (publ) Competitors

Price History & Performance

Summary of share price highs, lows and changes for Idogen
Historical stock prices
Current Share PriceSEK 0.12
52 Week HighSEK 0.55
52 Week LowSEK 0.015
Beta1.78
1 Month Change-20.20%
3 Month Change41.76%
1 Year Change-62.92%
3 Year Change-98.22%
5 Year Change-99.58%
Change since IPO-99.82%

Recent News & Updates

Recent updates

Shareholder Returns

IDOGENSE BiotechsSE Market
7D-5.5%-1.7%-0.4%
1Y-62.9%-3.0%-5.1%

Return vs Industry: IDOGEN underperformed the Swedish Biotechs industry which returned -6.6% over the past year.

Return vs Market: IDOGEN underperformed the Swedish Market which returned 4.4% over the past year.

Price Volatility

Is IDOGEN's price volatile compared to industry and market?
IDOGEN volatility
IDOGEN Average Weekly Movement194.5%
Biotechs Industry Average Movement9.3%
Market Average Movement6.8%
10% most volatile stocks in SE Market13.6%
10% least volatile stocks in SE Market4.2%

Stable Share Price: IDOGEN's share price has been volatile over the past 3 months.

Volatility Over Time: IDOGEN's weekly volatility has increased from 95% to 194% over the past year.

About the Company

FoundedEmployeesCEOWebsite
20086Christina Herderwww.idogen.com

Idogen AB (publ), a biotechnology company, develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs, and the body’s own cells or tissues in Sweden. The company’s advanced product candidate is IDO 8 that is designed for patients with severe haemophilia A, who have developed neutralizing antibodies against critical treatment with coagulation factor VIII. It also develops IDO T, a tolerogenic cell therapy to prevent organ transplant rejection primarily kidney transplantation; and IDO AID for the treatment of autoimmune diseases.

Idogen AB (publ) Fundamentals Summary

How do Idogen's earnings and revenue compare to its market cap?
IDOGEN fundamental statistics
Market capSEK 12.58m
Earnings (TTM)-SEK 44.05m
Revenue (TTM)SEK 771.00k

16.3x

P/S Ratio

-0.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IDOGEN income statement (TTM)
RevenueSEK 771.00k
Cost of RevenueSEK 0
Gross ProfitSEK 771.00k
Other ExpensesSEK 44.82m
Earnings-SEK 44.05m

Last Reported Earnings

Mar 31, 2023

Next Earnings Date

Aug 23, 2023

Earnings per share (EPS)-0.42
Gross Margin100.00%
Net Profit Margin-5,712.97%
Debt/Equity Ratio0%

How did IDOGEN perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/07/11 16:19
End of Day Share Price 2023/07/06 00:00
Earnings2023/03/31
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Idogen AB (publ) is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Klas PykNordea Markets
Maria Karlsson OsipovaPenser Access
Filip EinarssonRedeye